- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
When asked what the ideal patient is for the 4-drug combination of lenalidomide, bortezomib, and dexamethasone plus daratumumab, Fonseca responded that is the wrong question; rather, clinicians should consider if there are any patients who should not receive this regimen.
Minimal residual disease (MRD) testing has become central to myeloma treatment goals. As the most sensitive test for residual disease, MRD negativity is now the most important prognostic factor in myeloma. Four analyses support the predictive value of MRD status. Unknowns remain regarding discontinuing therapy with sustained MRD negativity and escalating therapy for persistent MRD positivity, although Fonseca tests patients routinely after transplant to guide next treatment steps aimed at achieving MRD negativity. While this must be done judiciously, he believes eliminating every myeloma cell should be the primary goal.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
